Pharmacotherapeutic advances for chronic idiopathic constipation in adults

References

• Lindberg G, Hamid SS, Malfertheiner P, et al. World gastroenterology organisation global guideline: constipation–a global perspective. J Clin Gastroenterol. 2011;45:483–4877.
   PubMed Web of Science ®Google Scholar
• Bharucha AE, Pemberton JH, Locke GR. American gastroenterological association technical review on constipation. Gastroenterology. 2013;144:218–238.
   PubMed Web of Science ®Google Scholar
• Neri L, Basilisco G, Corazziari E, et al. Constipation severity is associated with productivity losses and healthcare utilization in patients with chronic constipation. United European Gastroenterol J. 2014;2:138–147.
   PubMed Web of Science ®Google Scholar
• Peppas G, Alexiou VG, Mourtzoukou E, et al. Epidemiology of constipation in Europe and Oceania: a systematic review. BMC Gastroenterol. 2008;8:5.
   PubMed Web of Science ®Google Scholar
• Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study. Gastroenterology. 2021;160:99–114.e3.
   PubMed Web of Science ®Google Scholar
• Bassotti G, Gaburri M, Imbimbo BP, et al. Colonic mass movements in idiopathic chronic constipation. Gut. 1988;29:1173–1179.
   PubMed Web of Science ®Google Scholar
• Bassotti G, Chistolini F, Marinozzi G, et al. Abnormal colonic propagated activity in patients with slow transit constipation and constipation-predominant irritable bowel syndrome. Digestion. 2003;68:178–183.
   PubMed Web of Science ®Google Scholar
• Bassotti G, Villanacci V, Maurer CA, et al. The role of glial cells and apoptosis of enteric neurons in the neuropathology of intractable slow transit constipation. Gut. 2006;55:41–46.
   PubMed Web of Science ®Google Scholar
• Rossi E, Villanacci V, Fisogni S, et al. Chromosomal study of enteric glial cells and neurons by fluorescence in situ hybridization in slow transit constipation. Neurogastroenterol Motil. 2007;19:578–584.
   PubMed Web of Science ®Google Scholar
• Bassotti G, Villanacci V, Creţoiu D, et al. Cellular and molecular basis of chronic constipation: taking the functional/idiopathic label out. World J Gastroenterol. 2013;19:4099–4105.
   PubMed Web of Science ®Google Scholar
• Bellini M, Usai-Satta P, Bove A, et al. Chronic constipation diagnosis and treatment evaluation: the ”CHRO.CO.DI.T.E.” study. BMC Gastroenterol. 2017;17:11.
   PubMed Web of Science ®Google Scholar
• Daniali M, Nikfar S, Abdollahi M. An overview of interventions for constipation in adults. Expert Rev Gastroenterol Hepatol. 2020;14:721–732.
   PubMed Web of Science ®Google Scholar
• Brenner DM, Harris LA, Chang CH, et al. Real-world treatment strategies to improve outcomes in patients with chronic idiopathic constipation and irritable bowel syndrome with constipation. Am J Gastroenterol. 2022;117(4S):S21–S26.
   PubMed Web of Science ®Google Scholar
• Bassotti G, Usai Satta P, Bellini M. Chronic idiopathic constipation in adults: a review on current guidelines and emerging treatment options. Clin Exp Gastroenterol. 2021;14:413–428.
   PubMed Web of Science ®Google Scholar
• Gwynne RM, Bornstein JC. Luminal 5-HT4 receptors-A successful target for prokinetic actions. Neurogastroenterol Motil. 2019;31:e13708.
   PubMed Web of Science ®Google Scholar
• Daniali M, Nikfar S, Abdollahi M. An overview of the efficacy and safety of prucalopride for the treatment of chronic idiopathic constipation. Expert Opin Pharmacother. 2019;20:2073–2080.
   PubMed Web of Science ®Google Scholar
• Chedid V, Vijayvargiya P, Camilleri M. Elobixibat for the treatment of constipation. Expert Rev Gastroenterol Hepatol. 2018;12:951–960.
   PubMed Web of Science ®Google Scholar
• Vijayvargiya P, Camilleri M. Update on bile acid malabsorption: finally ready for prime time? Curr Gastroenterol Rep. 2018;20:10.
   PubMedGoogle Scholar
• Wong BS, Camilleri M, McKinzie S, et al. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol. 2011;106:2154–2164.
   PubMed Web of Science ®Google Scholar
• Chey WD, Camilleri M, Chang L, et al. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol. 2011;106:1803–1812.
   PubMed Web of Science ®Google Scholar
• Simrén M, Bajor A, Gillberg PG, et al. Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation–a double-blind study. Aliment Pharmacol Ther. 2011;34:41–50.
   PubMed Web of Science ®Google Scholar
• Nakajima A, Ishizaki S, Matsuda K, et al. Impact of elobixibat on serum and fecal bile acid levels and constipation symptoms in patients with chronic constipation. J Gastroenterol Hepatol. 2022;37:883–890.
   PubMed Web of Science ®Google Scholar
• Tomie A, Yoshida N, Kugai M, et al. The efficacy and safety of elobixibat for the elderly with chronic constipation: a multicenter retrospective cohort study. Gastroenterol Res Pract. 2020;2020:9656040.
   PubMed Web of Science ®Google Scholar
• Abe T, Kunimoto M, Hachiro Y, et al. Efficacy and safety of elobixibat in elderly patients with chronic constipation: a single-center, observational study. J Anus Rectum Colon. 2020; 4: 122–127.
   PubMed Web of Science ®Google Scholar
• Nakajima A, Fujimaki M, Arai Y, et al. Safety and efficacy of elobixibat, an ileal bile acid transporter inhibitor, in elderly patients with chronic idiopathic constipation according to administration time: interim analysis of post-marketing surveillance. J Neurogastroenterol Motil. 2022;28:431–441.
   PubMed Web of Science ®Google Scholar
• Nakajima A, Seki M, Taniguchi S, et al. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3:537–547.
   PubMed Web of Science ®Google Scholar
• Nakajima A, Seki M, Taniguchi S. Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial. J Gastroenterol. 2018;53:525–534.
   PubMed Web of Science ®Google Scholar
• Oduyebo I, Camilleri M, Nelson AD, et al. Effects of NGM282, an FGF19 variant, on colonic transit and bowel function in functional constipation: a randomized phase 2 trial. Am J Gastroenterol. 2018;113:725–734.
   PubMed Web of Science ®Google Scholar
• Kumagai Y, Amano H, Sasaki Y, et al. Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: a randomized controlled trial. Br J Clin Pharmacol. 2018;84:2393–2404.
   PubMed Web of Science ®Google Scholar
• Odaka T, Tominaga K. Uncontrolled, open-label pre-dinner administration of elobixibat in Japanese adults with chronic constipation: a retrospective chart review. Curr Ther Res Clin Exp. 2020;93:100616.
   PubMed Web of Science ®Google Scholar
• Eguchi T, Yoshizaki T, Ikeoka S, et al. Real-world comparison of elobixibat and lubiprostone treatment in patients with chronic constipation: a propensity score-matched analysis. Dig Dis. 2021;39:341–350.
   PubMed Web of Science ®Google Scholar
• Lacy BE, Levy LC. Lubiprostone: a chloride channel activator. J Clin Gastroenterol. 2007;41:345–351.
   PubMed Web of Science ®Google Scholar
• Fukudo S, Hongo M, Kaneko H, et al. Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. Neurogastroenterol Motil. 2011;23:544–e205.
   PubMed Web of Science ®Google Scholar
• Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther. 2007;25:1351–1361.
   PubMed Web of Science ®Google Scholar
• Johanson JF, Morton D, Geenen J, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol. 2008;103:170–177.
   PubMed Web of Science ®Google Scholar
• Barish CF, Drossman D, Johanson JF, et al. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci. 2010;55:1090–1097.
   PubMed Web of Science ®Google Scholar
• Fukudo S, Hongo M, Kaneko H, et al. Lubiprostone increases spontaneous bowel movement frequency and quality of life in patients with chronic idiopathic constipation. Clin Gastroenterol Hepatol. 2015;13:294–301.e5.
   PubMed Web of Science ®Google Scholar
• Christie J, Shroff S, Shahnavaz N, et al. A randomized, double-blind, placebo-controlled trial to examine the effectiveness of lubiprostone on constipation symptoms and colon transit time in diabetic patients. Am J Gastroenterol. 2017;112:356–364.
   PubMed Web of Science ®Google Scholar
• Cryer B, Drossman DA, Chey WD, et al. Analysis of nausea in clinical studies of lubiprostone for the treatment of constipation disorders. Dig Dis Sci. 2017;62:3568–3578.
   PubMed Web of Science ®Google Scholar
• Pennington B, Marriott ER, Lichtlen P, et al. The cost effectiveness of lubiprostone in chronic idiopathic constipation. Pharmacoecon Open. 2018;2:241–253.
   PubMed Web of Science ®Google Scholar
• Jarmuż A, Zielińska M, Storr M, et al. Emerging treatments in neurogastroenterology: perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases. Neurogastroenterol Motil. 2015;27:1057–1068.
   PubMed Web of Science ®Google Scholar
• Kamuda JA, Mazzola N. Plecanatide (Trulance) for chronic idiopathic constipation and irritable bowel syndrome with constipation. P T. 2018;43:207–232.
   PubMedGoogle Scholar
• Miner PB, Surowitz R, Fogel R, et al. Plecanatide, a novel guanylate cyclase-C (GC-C) receptor agonist, is efficacious and safe in patients with chronic idiopathic constipation (CIC): results from a 951 patient, 12 week, multi-center trial. Gastroenterology. 2013;144:S163.
   Web of Science ®Google Scholar
• Miner PB Jr, Koltun WD, Wiener GJ, et al. A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation. Am J Gastroenterol. 2017;112:613–621.
   PubMed Web of Science ®Google Scholar
• DeMicco M, Barrow L, Hickey B, et al. Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation. Therap Adv Gastroenterol. 2017;10:837–851.
   PubMed Web of Science ®Google Scholar
• Barish CF, Griffin P. Safety and tolerability of plecanatide in patients with chronic idiopathic constipation: long-term evidence from an open-label study. Curr Med Res Opin. 2018;34:751–755.
   PubMed Web of Science ®Google Scholar
• Barish C, Dorn S, Fogel RP, et al. Plecanatide is effective and safe in the treatment for chronic idiopathic constipation: results of a phase II trial. Dig Dis Sci. 2021;66:537–540.
   PubMed Web of Science ®Google Scholar
• Sharma A, Herekar AA, Bhagatwala J, et al. Profile of plecanatide in the treatment of chronic idiopathic constipation: design, development, and place in therapy. Clin Exp Gastroenterol. 2019;12:31–36.
   PubMed Web of Science ®Google Scholar
• Bassotti G, Blandizzi C. Understanding and treating refractory constipation. World J Gastrointest Pharmacol Ther. 2014;5:77–85.
   PubMedGoogle Scholar
• Bassotti G, Gambaccini D, Bellini M. Prucalopride succinate for the treatment of constipation: an update. Expert Rev Gastroenterol Hepatol. 2016;10:291–300.
   PubMed Web of Science ®Google Scholar
• Bassotti G, Usai Satta P, Bellini M. Prucalopride for the treatment of constipation: a view from 2015 and beyond. Expert Rev Gastroenterol Hepatol. 2019;13:257–262.
   PubMed Web of Science ®Google Scholar
• Al-Judaibi B, Chande N, Gregor J. Safety and efficacy of tegaserod therapy in patients with irritable bowel syndrome or chronic constipation. Can J Clin Pharmacol. 2010;17:e194–200.
   PubMedGoogle Scholar
• Pasricha PJ. Desperately seeking serotonin … A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders. Gastroenterology. 2007;132:2287–2290.
   PubMed Web of Science ®Google Scholar
• Lacy BE, Brenner DM, Chey WD. Re-evaluation of the cardiovascular safety profile of tegaserod: a review of the clinical data. Clin Gastroenterol Hepatol. 2022;20:e682–e695.
   PubMed Web of Science ®Google Scholar
• Shah ED, Lacy BE, Chey WD, et al. Tegaserod for irritable bowel syndrome with constipation in women younger than 65 years without cardiovascular disease: pooled analyses of 4 controlled trials. Am J Gastroenterol. 2021;116:1601–1611.
   PubMed Web of Science ®Google Scholar
• Bassotti G, Gambaccini D, Bellini M. Velusetrag for the treatment of chronic constipation. Expert Opin Investig Drugs. 2016;25:985–990.
   PubMed Web of Science ®Google Scholar
• Bowersox SS, Lightning LK, Rao S, et al. Metabolism and pharmacokinetics of naronapride (ATI-7505), a serotonin 5-HT(4) receptor agonist for gastrointestinal motility disorders. Drug Metab Dispos. 2011;39:1170–1180.
   PubMed Web of Science ®Google Scholar
• Long DD, Armstrong SR, Beattie DT, et al. Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation. Bioorg Med Chem Lett. 2012;22:6048–6052.
   PubMed Web of Science ®Google Scholar
• Manini ML, Camilleri M, Goldberg M, et al. Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil. 2010;22:42–49.
   PubMed Web of Science ®Google Scholar
• Goldberg M, Li YP, Johanson JF, et al. Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study. Aliment Pharmacol Ther. 2010;32:1102–1112.
   PubMed Web of Science ®Google Scholar
• Palme M, Milner PG, Ellis DJ, et al. A novel gastrointestinal prokinetic, ATI-7505, increased spontaneous bowel movements (Sbms) in a phase II, randomized, placebo-controlled study of patients with chronic idiopathic constipation (CIC). Gastroenterology. 2010;138:S128–S129.
   Web of Science ®Google Scholar
• Shin A, Camilleri M, Kolar G, et al. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther. 2014;39:239–253.
   PubMed Web of Science ®Google Scholar
• Luthra P, Camilleri M, Burr NE, et al. Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:831–844.
   PubMed Web of Science ®Google Scholar
• Beattie DT, Armstrong SR, Vickery RG, et al. The pharmacology of TD-8954, a potent and selective 5-HT(4) receptor agonist with gastrointestinal prokinetic properties. Front Pharmacol. 2011;2:25.
   PubMed Web of Science ®Google Scholar
• Shin A, Acosta A, Camilleri M, et al. A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. Clin Gastroenterol Hepatol. 2015;13:701–708.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Acosta A. Emerging treatments in neurogastroenterology: relamorelin: a novel gastrocolokinetic synthetic ghrelin agonist. Neurogastroenterol Motil. 2015;27:324–332.
   PubMed Web of Science ®Google Scholar
• Mosińska P, Zatorski H, Storr M, et al. Future treatment of constipation-associated disorders: role of relamorelin and other ghrelin receptor agonists. J Neurogastroenterol Motil. 2017;23:171–179.
   PubMed Web of Science ®Google Scholar
• Acosta A, Camilleri M, Kolar G, et al. Relamorelin relieves constipation and accelerates colonic transit in a phase 2, placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2015;13:2312–2319.
   PubMed Web of Science ®Google Scholar
• Acosta A, Camilleri M, Busciglio I, et al. Short-term effects of relamorelin on descending colon motility in chronic constipation: a randomized, controlled trial. Dig Dis Sci. 2016;61:852–860.
   PubMed Web of Science ®Google Scholar
• Bassotti G. Relamorelin to treat constipation: ”pusher” or pushover? Dig Dis Sci. 2016;61:658–659.
   PubMed Web of Science ®Google Scholar
• Battaglia E, Grassini M, Dore MP, et al. Usefulness of bisacodyl testing on therapeutic outcomes in refractory constipation. Dig Dis Sci. 2018;63:3105–3111.
   PubMed Web of Science ®Google Scholar
• Inoue T, Takemura M, Fushimi N, et al. Mizagliflozin, a novel selective SGLT1 inhibitor, exhibits potential in the amelioration of chronic constipation. Eur J Pharmacol. 2017;806:25–31.
   PubMed Web of Science ®Google Scholar
• Fukudo S, Endo Y, Hongo M, et al. Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial. Lancet Gastroenterol Hepatol. 2018;3:603–613.
   PubMed Web of Science ®Google Scholar
• Staller K, Barshop K, Vélez C, et al. CSP01, a novel superabsorbent hydrogel, reduces colonic transit time in patients with chronic idiopathic constipation in a randomized, double-blind, controlled pilot clinical trial. J Neurogastroenterol Motil. 2020;26:496–504.
   PubMed Web of Science ®Google Scholar
• Basilisco G; Italian Society of Neurogastroenterology Motility (SINGEM) Study Group. Patient dissatisfaction with medical therapy for chronic constipation or irritable bowel syndrome with constipation: analysis of N-of-1 prospective trials in 81 patients. Aliment Pharmacol Ther. 2020;51:629–636.
   PubMed Web of Science ®Google Scholar
• Bassotti G. New pharmacologic treatments for idiopathic chronic constipation: a financial strain for strainers. Expert Rev Gastroenterol Hepatol. 2021;15:723–725.
   PubMed Web of Science ®Google Scholar
• Morrow T. $850 per bowel movement?! Hard to justify that cost. Manag Care. 2017;26:36–37.
   Google Scholar
• Han D, Iragorri N, Clement F, et al. Cost effectiveness of treatments for chronic constipation: a systematic review. Pharmacoeconomics. 2018;36:435–449.
   PubMed Web of Science ®Google Scholar
• Shah ED, Staller K, Nee J, et al. Evaluating the impact of cost on the treatment algorithm for chronic idiopathic constipation: cost-effectiveness analysis. Am J Gastroenterol. 2021;116:2118–2127.
   PubMed Web of Science ®Google Scholar